Drug Profile
S 32730
Latest Information Update: 20 Sep 1999
Price :
$50
*
At a glance
- Originator Kaken Pharmaceutical
- Class Antibacterials; Quinolones
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections